Global neuroendocrine
carcinoma therapeutics market is witnessing significant growth due to large
number of marketed drugs and Phase III drugs. Neuroendocrine carcinoma is a
tumor that begins in neuroendocrine cells and can spread, or metastasize, to
other parts of the body. It starts in the hormone producing cells of the body’s
neuroendocrine system. Neuroendocrine tumors can begin in many organs
including, lungs, brain and gastrointestinal tract. It is a very rare cancer
with symptoms such as hyperglycemia, hypoglycemia, diarrhea, weight loss, pain,
cough, lump formation, jaundice, unusual bleeding, headache and anxiety. The
risk factors of developing neuroendocrine cancer includes, age, gender, family
history, immune system suppression, arsenic exposure and sun exposure. The
diagnosis can be done by normal physical examination followed by blood tests,
urine tests, X- ray, CT scan, PET scan, MRI and biopsy.
The
treatments available for neuroendocrine tumor include chemotherapy, surgery and
radiation therapy. Chemotherapy comprises the drug’s use to destroy malignant
cells by hindering the cells ability to divide and grow. Streptozocin (Zanosar)
and 5-fluorouracil (Adrucil, 5-FU) are some of the drugs that are used to treat
neuroendocrine tumors. Many pharmaceutical companies have been working
continuously for the development of targeted therapy for the growth of
neuroendocrine cancer market.
Request to Get the Sample Pages at:
Sunitinib
(Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being
used for treatment of neuroendocrine cancer. Genentech Inc., F. Hoffmann-La
Roche Ltd., Callisto Pharmaceuticals Pvt. Ltd. and BioSynthema, Inc. are some
major companies that are determined to develop therapeutics for various
neuroendocrine cancers. Lutathera, Atiprimod and Avastin are pipeline
candidates that are presently being studied for their therapeutic efficacy in
the treatment of neuroendocrine cancer. Also, there are many other pipeline
drugs in Phase III which are expected to enter the neuroendocrine carcinoma
therapeutics market in the future.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=neuroendocrine-carcinoma-therapeutics-market
Geographically,
neuroendocrine carcinoma therapeutics market has been segmented into North
America, Europe, Asia Pacific and Rest of the World (RoW). According to
Cancer.Net, approximately 8,000 people are identified with neuroendocrine cancer
every year in the U.S. Several key players functioning in neuroendocrine
carcinoma therapeutics market are based in the U.S and therefore consider North
America as their main market for product launch and research and development
investments. Also, entrenched infrastructure and favorable reimbursement
scenario are the major factors accountable for the strengthening of North
America’s neuroendocrine carcinoma therapeutics market. Europe is the second
largest market for neuroendocrine carcinoma therapeutics, followed by Asia.
Increasing prevalence of neuroendocrine cancer in Asia Pacific along with the
refining economic scenario is expected to play an important role in driving the
market growth in the region.
Some of the
key players operating in the global
neuroendocrine carcinoma therapeutics market include Pfizer Ltd., Eli
Lilly & Company, Novartis AG, F. Hoffmann-La Roche Ltd., Ispen SA, Amgen,
Inc., Teva Pharmaceuticals, Ltd. and Bristol-Myers Squibb among others.
